Birmingham Hematology and Oncology

Birmingham, Alabama 35235

0 studies enrolling now · 11 studies all time

What they study most

Breast Cancer, Carcinoid Tumor, Gastric Cancer Adenocarcinoma Metastatic, Hormone Refractory Prostate Cancer, Lymphoma, T-Cell, Peripheral, Metastatic Breast Cancer, Neuroendocrine Tumors, Prostate Cancer

Studies at this site

• PhII ICb With/Without Erbitux in MBC Pts — Running, not enrolling
• TAC Versus TC for Adjuvant Breast Cancer — Completed
• A Clinical Trial Comparing the Combination of TC Plus Bevacizumab to TC Alone and to TAC for Women With Node-Positive or High-Risk Node-Negative, HER2-Negative Breast Cancer — Completed
• A Study of ONTAK and CHOP in Newly Diagnosed, Peripheral T-Cell Lymphoma — Completed
• Docetaxel+Oxali+/-Cetux Met Gastric/GEJ — Completed
• Doxil & Carboplatin Plus HER2+ in Metastatic Breast Cancer — Completed
• Adj TC + Herceptin Early Stage Breast Cancer — Completed
• A Phase II Study of E7389 in Patients With Breast Cancer, Previously Treated With Anthracycline, Taxane and Capecitabine — Completed
• Expanded Access Study of Satraplatin Plus Prednisone in Patients With Hormone Refractory Prostate Cancer (HRPC) — Stopped early
• Satraplatin in Hormone Refractory Prostate Cancer Patients Previously Treated With One Cytotoxic Chemotherapy Regimen — Completed
• Quarfloxin in Patients With Low to Intermediate Grade Neuroendocrine Carcinoma — Completed